The original disclosure in Japanese was released on August 3, 2021 at 15:00 (GMT+8)

To whom it may concern:

August 3, 2021
CompanyHeadquarters
RepresentativeContact
Telephone
WebsiteTakara Bio Inc. (First Section TSE, code: 4974)
Nojihigashi 7-4-38, Kusatsu, Shiga, Japan
Koichi Nakao, President & CEO
Takuya Kakemi, Executive Officer, President ofCorporate Management Division,(+81)77-565-6970
https://www.takara-bio.co.jp/

Notice of Revision of Financial Forecast and Dividend Forecast (Dividend Increase)
Kusatsu/Shiga, Japan-August 3, 2021 – Takara Bio Inc. (Takara Bio), announced the revision of the consolidated
financial forecast and the dividend forecast for the fiscal year ending March 31, 2022 (April 1, 2021 – March31, 2022) that was disclosed on May 13, 2021, as follows based on a review of current trends in results ofoperations.

1. Revisions to Financial Forecast(1) Revisions to the Consolidated Forecasts for the first half of the fiscal year ending March 2022(April 1, 2021-September 30, 2021)

Previous forecast (A)Revised forecast (B)Change (B-A)
Change (%)(Reference)
Results for the first halfof the previous fiscal year
ended March 31, 2021

Net profit

Net incomeper share

Net sales

OperatingProfit

OrdinaryProfit

Millions yen

Millions yen

Millions yen

Millions yen

24,60929,700
5,090
20.7

7,139
11,400
4,260
59.7

7,220
11,400
4,180
57.9

4,889
7,900
3,010
61.6

Yen
40.61
65.61
-

17,393

3,736

3,820

2,274

18.89

attributable toowners of parent(2) Revisions to the Consolidated Forecasts for the fiscal year ending March 2022
(April 1, 2021-March 31, 2022)

Previous forecast (A)Revised forecast (B)Change (B-A)
Change (%)(Reference)
Results for the previous
fiscal year ended March
31, 2021

Net sales

OperatingprofitOrdinary
profitMillions yen
50,50054,2003,700
7.3

Millions yen
14,00017,0003,000
21.4

Millions yen
14,20017,1002,900
20.4

46,086

13,952

14,159-1-

Net profit
attributable toowners of parent

Net income
per share

Millions yen
9,800
11,900
2,100
21.4

Yen
81.38
98.82
-9,547

79.29

The original disclosure in Japanese was released on August 3, 2021 at 15:00 (GMT+8)(3) Reason for the Revision
The forecasts for the first half and the full fiscal year have been revised from the forecasts announced on May
13, 2021, based on recent conditions.
In terms of net sales, in addition to the recovery in the general research reagent market, which had beensluggish due to the impact of the new Coronavirus, PCR testing-related products for the virus are also
expected to increase. Moreover CDMO business, such as outsourcing related to genetic analysis, is expected
to increase. As a result, net sales are expected to exceed the forecast as a whole.
With regard to SG&A expenses, while R&D expenses will increase from the initial plan, the increase ingross profit due to the increase in sales will be larger than the increase of SG&A expenses. As a result
operating income, ordinary income, and net income attributable to owners of the parent are expected toexceed the previous forecast. For the reasons stated above, the forecasts for the first half and the full fiscal
year have been revised.
For details of the forecast announced this time, please refer to page 11-12 of the "Financial Results for theFirst Quarter of the Fiscal Year Ending March 31, 2022" announced today.
2. Revision to Dividend Forecast(1) Details of Revised Dividend Forecast
Record Date
Previous forecast
Revised forecast
Actual results
Results for the previous
fiscal year ended March31, 2021)

End of first half
0.00 yen
0.00 yen

Cash dividends per share (yen)Year-end
16.00 yen
20.00 yen

Total
16.00 yen
20.00 yen

0.00 yen

16.00 yen

16.00 yen

(2) Reason for the Revision
Considering the management performance and financial statement comprehensively, Takara Bio recognizes
a basic policy aimed for profit contribution, positioning an important business management issue todistribute profits to shareholders as well as enhancing the internal reserves to strengthen the researchdevelopment activities in Bioindustry and Gene Therapy businesses. Specifically, the dividends of surplus
will be paid at around 20% of estimated profit calculated without considering extraordinary income or loss
in the consolidated financial statements.
Based on the above upward revision of the full-year consolidated results forecast and the above shareholder return
policy, Takara Bio has revised the year-end distribution forecast for the year ending March 2022 from 16.00 to20.00 per share.
The year-end dividend for the fiscal year ending March 31, 2022 is scheduled to be discussed at the 20th
Ordinary General Meeting of Shareholders to be held in June 2022.

Notes on handling this material
Statements made in this document with respect to our current plans, estimates, strategies, beliefs and other statements thatare not historical facts are forward-looking statements about our future performance, which are based on our management'sbeliefs in light of information currently available, but which are based on a number of assumptions and beliefs in light of
information that involves substantial risks and uncertainties. Please be aware that actual results may differ materially fromthese forecasts due to various factors. Factors that could influence actual results include, but are not limited to, economicconditions, especially trends in consumer spending, as well as exchange rate fluctuations, changes in laws and governmentsystems, pressure from competitors' prices and product strategies, declines in selling power of the Company's existing andnew products, disruptions to production, violations of our intellectual property rights, rapid advances in technology, andunfavorable verdicts in major litigation.

-2-